Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

SmithKline Avandia Launch In EU Delayed By Negative CPMP Vote

  • News

Executive Summary

SmithKline Beecham will work with European regulators over the next several months to persuade them to reverse a negative opinion from the Committee for Proprietary Medicinal Products regarding the approval of its antidiabetic Avandia (rosiglitazone).

You may also be interested in...



SmithKline Avandia Recommended Only For Combination Use By CPMP

SmithKline Beecham's thiazolidinedione antidiabetic Avandia is in the final stages of EU approval following a positive recommendation by the Committee for Proprietary Medicinal Products March 16.

SmithKline Avandia Recommended Only For Combination Use By CPMP

SmithKline Beecham's thiazolidinedione antidiabetic Avandia is in the final stages of EU approval following a positive recommendation by the Committee for Proprietary Medicinal Products March 16.

Prozac New Prescription Share Declines; Celexa, Effexor Make Gains

Lilly Prozac's share of new prescriptions declined four percentage points year to date, according to IMS Health data.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

See All
UsernamePublicRestriction

Register

PS035064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By